Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.

Shaw R, Yoon JJ, Johnston H, Davidson MB, Siddon AJ, Shallis RM, Chen EC, Burkart M, Oh TS, Iyer SG, Madarang E, Muthiah C, Kassner J, Rampal RK, Guru Murthy GS, Bradley T, Abaza Y, Garcia JS, Gupta V, Pettit KM, Odenike O, Patel AA

Open source

DOI: 10.1182/bloodadvances.2024015712
Published: 2025 May 27
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2024015712,
  title = {Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.},
  author = {Shaw R and Yoon JJ and Johnston H and Davidson MB and Siddon AJ and Shallis RM and Chen EC and Burkart M and Oh TS and Iyer SG and Madarang E and Muthiah C and Kassner J and Rampal RK and Guru Murthy GS and Bradley T and Abaza Y and Garcia JS and Gupta V and Pettit KM and Odenike O and Patel AA},
  year = {2025},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2024015712},
  url = {https://doi.org/10.1182/bloodadvances.2024015712}
}

RIS

TY  - JOUR
TI  - Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.
AU  - Shaw R
AU  - Yoon JJ
AU  - Johnston H
AU  - Davidson MB
AU  - Siddon AJ
AU  - Shallis RM
AU  - Chen EC
AU  - Burkart M
AU  - Oh TS
AU  - Iyer SG
AU  - Madarang E
AU  - Muthiah C
AU  - Kassner J
AU  - Rampal RK
AU  - Guru Murthy GS
AU  - Bradley T
AU  - Abaza Y
AU  - Garcia JS
AU  - Gupta V
AU  - Pettit KM
AU  - Odenike O
AU  - Patel AA
PY  - 2025
JO  - Blood advances
DO  - 10.1182/bloodadvances.2024015712
UR  - https://doi.org/10.1182/bloodadvances.2024015712
ER  -

APA

R, S., JJ, Y., H, J., MB, D., AJ, S., RM, S., EC, C., M, B., TS, O., SG, I., E, M., C, M., J, K., RK, R., GS, G. M., T, B., Y, A., JS, G., V, G., KM, P., O, O., & AA, P. (2025). Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.. Blood advances. https://doi.org/10.1182/bloodadvances.2024015712

Source records

pubmed · retrieved 2026-09-26T04:02:19.190Z